Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Post by Bullknit101on Jan 02, 2021 10:48am
120 Views
Post# 32209259

Happy New Year

Happy New Year To all InMed investors, wishing you a prosperous year. Looking closely at the Cannabis sector (&related), I predict that the big winners will be US MSOs, Village Farms and Cannabinoid Biosynthetic companies. InMed is the only NASDAQ traded biosynthetic company and has an incredible valuation. Market cap is low and share float is low. They haven't made as much noise as Willow and others (long quiet period due to IPO), but it's certainly the best play in this space. Their partner Almac has the supply chain they need as well access to 25 of the largest pharma companies in the world (does Willow have that?). I fully expect news in January (letter to shareholders, INM-755-102 update, scale-up at Almac progress, investment reports etc.). Good luck to all.
<< Previous
Bullboard Posts
Next >>